Humacyte

IPO

Universally Implantable Regenerative Human Tissues - Humacyte Global, Inc.

Public · Durham, United States · Founded 2004 · $235.0M raised

Headquarters
Durham
Employees
201–500
Founded
2004
Business Model
B2B
Total Funding
$235.0M
Last Round
$10.0M Corporate RoundMay 2023
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Humacyte is a commercial-stage biotechnology company headquartered in Durham, North Carolina, pioneering a platform for the investigation, development, and manufacture of bioengineered human tissues and organs designed to be universally implantable, off-the-shelf, and regenerative. Its lead product, Symvess, is an FDA-approved bioengineered vessel used in vascular repair, and the company's broader technology platform aims to treat a wide variety of diseases, injuries, and chronic conditions without relying on donor-matched tissue.

Summary

Humacyte is a Biotech company based in Durham, United States, founded in 2004. It has raised $235.0M in total across 4 rounds, most recently a $10.0M Corporate Round in May 2023. Investors include Oberland Capital, Alpha Healthcare Acquisition Corp and PointState Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Secondary MarketSecondary MarketMar 2026

Sign up to see all 7 events

Funding: Series B through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Humacyte on Indexed.vc
<a href="https://indexed.vc/companies/humacyte"><img src="https://indexed.vc/api/badge/company/humacyte" alt="Humacyte on Indexed.vc" width="260" height="76" /></a>